PLATAFORMA CIENTIFICA PASTEUR USP/USP
(Institutional affiliation for the last research proposal)
Graduated in Biological Sciences from the Federal University of Rio de Janeiro (1978), Master's degree in Biological Sciences (Biophysics) from the Federal University of Rio de Janeiro (1982) and PhD in Biological Sciences (Biophysics) from the Federal University of Rio de Janeiro (1985) ). Conducted postdoctoral internships at the Max-Planck Institute in Tuebingen, Germany (1986/7), Vaccine Development Center at the University of Maryland, USA (1991), Department of Microbiology and Molecular Biology, Tufts University, USA (1992 ) and Department of Medical Microbiology at the University of Gothenburg, Sweden (1996). Visiting researcher at the Institute of Genetics, University of Bayreuth, Germany (2000-2005). Adjunct professor at the Biophysics and Radiobiology Department at the Federal University of Pernambuco (1983-1989) and at the Carlos Chagas Filho Biophysics Institute at the Federal University of Rio de Janeiro (1989-2000). He is currently a full professor (1999) and a full professor (2000) at the University of São Paulo and responsible for the Vaccine Development Laboratory in the Department of Microbiology at the Institute of Biomedical Sciences. Researcher 1A of the National Council for Scientific and Technological Development (until 2023). Coordinator of the Vaccine Research Support Center at USP. Vice-director of the USP Biomedical Sciences Institute (2013-2017). Director of the USP Biomedical Sciences Institute (2017-2021). Coordinator of the Scientific Platform Pasteur-USP (2018-2022). He received several awards related to scientific work and technological innovation. He has experience in the areas of Microbiology, Molecular Genetics and Microorganisms, immunology and vaccine development. He works on research related to the development of different vaccine strategies, among them research on vaccines aimed at controlling diarrhea caused by enteric bacteria (diarrhogenic Escherichia coli), dengue, dental caries and tumors induced by papillomavirus. He also conducts research related to the development of new vaccine adjuvants of a microbial nature. He develops projects in partnership with companies such as GSK, Instituto Butantan and Fundação Oswaldo Cruz. He has published about 200 scientific articles in specialized journals and has 9 patent applications filed with the INPI and / or PCT.
(Source: Lattes Curriculum)
Articles published in Pesquisa FAPESP Magazine about the researcher: